We are live on ! Find out more
CVS icon

CVS Health

1,654 hedge funds and large institutions have $54.6B invested in CVS Health in 2019 Q2 according to their latest regulatory filings, with 123 funds opening new positions, 754 increasing their positions, 660 reducing their positions, and 154 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more funds holding in top 10

Funds holding in top 10: 3548 (+13)

14% more repeat investments, than reductions

Existing positions increased: 754 | Existing positions reduced: 660

1% less capital invested

Capital invested by funds: $55.1B → $54.6B (-$425M)

1.44% less ownership

Funds ownership: 78.75%77.31% (-1.4%)

3% less funds holding

Funds holding: 1,7081,654 (-54)

20% less first-time investments, than exits

New positions opened: 123 | Existing positions closed: 154

20% less call options, than puts

Call options by funds: $1.14B | Put options by funds: $1.44B

Holders
1,654
Holders Change
-54
Holders Change %
-3.16%
% of All Funds
35.92%
Holding in Top 10
48
Holding in Top 10 Change
+13
Holding in Top 10 Change %
+37.14%
% of All Funds
1.04%
New
123
Increased
754
Reduced
660
Closed
154
Calls
$1.14B
Puts
$1.44B
Net Calls
-$291M
Net Calls Change
+$32.6M
Name Holding Trade Value Shares
Change
Change in
Stake
GI
176
GAMCO Investors
Connecticut
$28.8M -$50.6K -939 -0.2%
APG Asset Management
177
APG Asset Management
Netherlands
$28.3M -$9.24M -171,619 -22%
Robeco Institutional Asset Management
178
Robeco Institutional Asset Management
Netherlands
$28.2M -$1.08M -20,101 -4%
CWG
179
C WorldWide Group
Denmark
$28.1M -$1.05M -19,567 -4%
ACI
180
AMP Capital Investors
Australia
$27.8M -$1.55M -28,750 -5%
TCA
181
Taconic Capital Advisors
New York
$27.5M +$2.15M +40,000 +9%
Axa
182
Axa
France
$27.4M -$138K -2,559 -0.5%
Royal London Asset Management
183
Royal London Asset Management
United Kingdom
$27.2M -$1.12M -20,835 -4%
MSE
184
MUFG Securities EMEA
United Kingdom
$27.1M -$3.45M -63,984 -11%
Nomura Asset Management
185
Nomura Asset Management
Japan
$26.6M +$2.25M +41,808 +9%
CA
186
Cortland Associates
Missouri
$26.6M -$586K -10,884 -2%
PR
187
Payden & Rygel
California
$26.5M +$12.4M +229,800 +89%
SCP
188
Seizert Capital Partners
Michigan
$26.3M -$2.35M -43,696 -8%
OPERF
189
Oregon Public Employees Retirement Fund
Oregon
$25.9M +$4.68M +86,827 +22%
CAM
190
Cacti Asset Management
Georgia
$25.8M +$53.9K +1,000 +0.2%
JIC
191
Johnson Investment Counsel
Ohio
$25.6M +$766K +14,222 +3%
RFC
192
Regions Financial Corp
Alabama
$25.5M +$3.11M +57,686 +14%
PI
193
PEAK6 Investments
Illinois
$25.4M -$15.9M -294,696 -39%
Mariner
194
Mariner
Kansas
$24.8M +$2.15M +39,881 +10%
BA
195
Bridgewater Associates
Connecticut
$24.4M -$10.2M -189,199 -30%
SCM
196
Stevens Capital Management
Pennsylvania
$24.2M +$12.5M +231,718 +109%
Nisa Investment Advisors
197
Nisa Investment Advisors
Missouri
$24M -$3.24M -60,242 -12%
CAM
198
Cidel Asset Management
Ontario, Canada
$23.9M +$9.59M +178,111 +69%
DIA
199
Dana Investment Advisors
Wisconsin
$23.8M -$3.43M -63,768 -13%
KBC Group
200
KBC Group
Belgium
$23.5M +$105K +1,943 +0.5%

CVS Hedge Fund Activity: Q2 2019 in Review

1,654 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in CVS Health (CVS) for Q2 2019, worth a combined $54.6B — down 0.77% from $55.1B a quarter earlier.

Sellers outnumbered buyers: 154 funds closed out of CVS and 123 opened new positions — a net loss of 31 holders — while 660 trimmed existing stakes and 754 added.

The largest buyer was Nuveen, adding an estimated $648M. The largest seller was T. Rowe Price Associates, cutting an estimated $321M.

  • 1,654 institutional investors held CVS Health (CVS) as of Q2 2019, down from 1,708 in Q1 2019.
  • Funds reported $54.6B of CVS Health stock for Q2 2019, down 0.77% quarter-over-quarter.
  • 123 funds opened new CVS Health positions in Q2 2019 and 154 closed out, a net change of -31 holders.
  • The largest CVS Health buyer in Q2 2019 was Nuveen, an estimated $648M added.
  • The largest CVS Health seller in Q2 2019 was T. Rowe Price Associates, an estimated $321M sold.

Based on aggregated 13F filings for Q2 2019.